Genetic risk score tracked melanoma cases in older ASPREE trial group
Bakshi and colleagues tested a 55-variant polygenic risk score for cutaneous melanoma in 12,712 participants of the ASPirin in Reducing Events in the Elderly trial. Mean age at baseline was 75. Over a median follow-up of 4.7 years, the score was associated with incident melanoma (hazard ratio 1.46 per standard deviation) and with prevalent melanoma (odds ratio 1.55 per standard deviation). Participants in the highest-risk group had roughly two to four times the odds of melanoma compared with those in the lowest-risk group.
The score tracked melanoma risk in this older group and may help identify who needs closer skin surveillance.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].